Streptozocin (Zanosar)
General information
Class/mechanism: Nitrosourea, alkylates DNA and RNA, antibiotic oncologic, mechanism not fully understood. Streptozocin has been observed to have greater toxicity to pancreatic islet beta cells, possibly because streptozocin can be transported into beta cells via the glucose transport protein GLUT2.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Diseases for which it was used
Patient drug information
- Streptozocin (Zanosar) patient drug information from manufacturer[4]
- Streptozocin (Zanosar) patient drug information (Chemocare)[5]
- Streptozocin (Zanosar) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 5/7/1982: Initial FDA approval
Also known as
- Generic name: STZ
- Brand name: Zanosar
References
- ↑ 1.0 1.1 Streptozocin (Zanosar) package insert
- ↑ Streptozocin (Zanosar) package insert (locally hosted backup)
- ↑ Zanosar manufacturer's website
- ↑ Streptozocin (Zanosar) patient information from manufacturer
- ↑ Streptozocin (Zanosar) patient drug information (Chemocare)
- ↑ Streptozocin (Zanosar) patient drug information (UpToDate)